Condition: Prostate Cancer · Sponsor: University Hospital, Geneva
The main objective of the phase I/II trial is to determine the safety and efficacy of a single fraction SBRT at a dose of 19 Gy in patients with localized prostate cancer.
This description comes directly from the study's public registry record.
Thomas Zilli, MD · +41 79 55 32 563 · Thomas.Zilli@hcuge.ch
Laurence Zulianello, PhD · + 22 372 72 05 · laurence.zulianello@hcuge.ch
Always discuss trial participation with your own doctor first.
| University Hospital of Geneva | Geneva, Switzerland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03294889